[
    [
        {
            "time": "2018-03-25",
            "original_text": "复星国际2018年净利134亿元 连续7年保持增长",
            "features": {
                "keywords": [
                    "复星国际",
                    "净利润",
                    "增长"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星国际2018年净利134亿元 连续7年保持增长",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星国际2018年总收入首破一千亿元",
            "features": {
                "keywords": [
                    "复星国际",
                    "总收入",
                    "突破"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星国际2018年总收入首破一千亿元",
                "Correlation": 9,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星国际(00656.HK)2018年净利升1.86%至134.06亿元 每股派息0.37港元。",
            "features": {
                "keywords": [
                    "复星国际",
                    "净利润",
                    "派息"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星国际(00656.HK)2018年净利升1.86%至134.06亿元 每股派息0.37港元。",
                "Correlation": 10,
                "Sentiment": 8,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "医疗科技行业头名独角兽，微医决定再次组织升级",
            "features": {
                "keywords": [
                    "医疗科技",
                    "微医",
                    "升级"
                ],
                "sentiment_score": 0.75,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "false",
                "causal_impact": "neutral",
                "affected_by_time_series": "false",
                "ts_effect_direction": "neutral"
            },
            "scores": {
                "News_content": "医疗科技行业头名独角兽，微医决定再次组织升级",
                "Correlation": 3,
                "Sentiment": 7,
                "Importance": 6,
                "Impact": 4,
                "Duration": 5,
                "Entity_Density": 2,
                "Market_Scope": 7,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "[中信建投医药】复星医药(600196)简评：研发投入充分， 创新逐步兑现",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发投入",
                    "创新"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "[中信建投医药】复星医药(600196)简评：研发投入充分， 创新逐步兑现",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 7,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星系“拧紧过日子” 近期密集减持6家上市公司",
            "features": {
                "keywords": [
                    "复星系",
                    "减持",
                    "上市公司"
                ],
                "sentiment_score": -0.7,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星系“拧紧过日子” 近期密集减持6家上市公司",
                "Correlation": 9,
                "Sentiment": 4,
                "Importance": 8,
                "Impact": 8,
                "Duration": 6,
                "Entity_Density": 9,
                "Market_Scope": 6,
                "Time_Proximity": 7,
                "Headline_Structure": 9,
                "Source_Recency": 7
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星医药年度报告：全年归母净利润27.08亿元 同比下降13.33%",
            "features": {
                "keywords": [
                    "复星医药",
                    "净利润",
                    "下降"
                ],
                "sentiment_score": -0.6,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星医药年度报告：全年归母净利润27.08亿元 同比下降13.33%",
                "Correlation": 10,
                "Sentiment": 3,
                "Importance": 9,
                "Impact": 9,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星前高管辞职2年首次发声：已退出复星国际顶层架构 董监高成员变化",
            "features": {
                "keywords": [
                    "复星国际",
                    "高管",
                    "辞职"
                ],
                "sentiment_score": -0.5,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "金融"
                ],
                "causal_factor": "true",
                "causal_impact": "negative",
                "affected_by_time_series": "true",
                "ts_effect_direction": "negative"
            },
            "scores": {
                "News_content": "复星前高管辞职2年首次发声：已退出复星国际顶层架构 董监高成员变化",
                "Correlation": 8,
                "Sentiment": 5,
                "Importance": 7,
                "Impact": 6,
                "Duration": 6,
                "Entity_Density": 8,
                "Market_Scope": 4,
                "Time_Proximity": 6,
                "Headline_Structure": 9,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星医药2018增长最快为药品制造与研发 总营收则为249.18亿元",
            "features": {
                "keywords": [
                    "复星医药",
                    "药品制造",
                    "研发",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药2018增长最快为药品制造与研发 总营收则为249.18亿元",
                "Correlation": 9,
                "Sentiment": 7,
                "Importance": 8,
                "Impact": 7,
                "Duration": 7,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 7,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星医药（600196）：2019年起创新药逐步进入收获期",
            "features": {
                "keywords": [
                    "复星医药",
                    "创新药",
                    "收获期"
                ],
                "sentiment_score": 0.9,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药（600196）：2019年起创新药逐步进入收获期",
                "Correlation": 9,
                "Sentiment": 8,
                "Importance": 8,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 9,
                "Market_Scope": 5,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星医药：全年研发投入达25亿，2019年创新药进入收获期",
            "features": {
                "keywords": [
                    "复星医药",
                    "研发投入",
                    "创新药",
                    "收获期"
                ],
                "sentiment_score": 0.85,
                "policy_related": "false",
                "investment_strategy": "true",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药：全年研发投入达25亿，2019年创新药进入收获期",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 9,
                "Entity_Density": 10,
                "Market_Scope": 5,
                "Time_Proximity": 6,
                "Headline_Structure": 8,
                "Source_Recency": 6
            }
        },
        {
            "time": "2018-03-25",
            "original_text": "复星医药2018年营收249.18亿元 同比增长34.45%",
            "features": {
                "keywords": [
                    "复星医药",
                    "营收",
                    "增长"
                ],
                "sentiment_score": 0.8,
                "policy_related": "false",
                "investment_strategy": "false",
                "sector_focus": [
                    "医疗"
                ],
                "causal_factor": "true",
                "causal_impact": "positive",
                "affected_by_time_series": "true",
                "ts_effect_direction": "positive"
            },
            "scores": {
                "News_content": "复星医药2018年营收249.18亿元 同比增长34.45%",
                "Correlation": 10,
                "Sentiment": 9,
                "Importance": 9,
                "Impact": 8,
                "Duration": 8,
                "Entity_Density": 10,
                "Market_Scope": 4,
                "Time_Proximity": 5,
                "Headline_Structure": 8,
                "Source_Recency": 5
            }
        }
    ]
]